News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Metaphore Pharmaceuticals, Inc. To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference


10/19/2005 5:12:45 PM

FT. LEE, N.J., Feb. 17 /PRNewswire-FirstCall/ -- Metaphore Pharmaceuticals, Inc., an emerging pharmaceutical company developing drugs for the treatment of pain, autoimmune disorders and inflammation, today announced that President and Chief Executive Officer Alan W. Dunton, M.D. will participate in a focus session at next week's 7th Annual BIO CEO & Investor Conference in New York.

The session, entitled "Cure the Pain - Reap the (Overlooked) Gain," is scheduled to take place from 4:00 to 5:30 p.m. ET Wednesday, February 23 in the Louis XVI Suite Center/West at the Waldorf-Astoria, 301 Park Avenue.

An archived audio Webcast of the event will be available 24 hours after the session on the bio.org web site and via the following link: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=28873&item_id=1009752

More about the Company

Metaphore Pharmaceuticals, Inc. is a privately held, emerging pharmaceutical company which discovers, develops and will market drugs that prevent and treat pain, autoimmune disorders and inflammation. The company leverages its expertise to discover and develop small molecule compounds that mimic the activity of human enzymes. Metaphore's lead compounds mimic the function of superoxide dismutase (SOD), a beneficial enzyme that serves an important protective role in the body by removing superoxide, a toxic free radical that can damage cells and tissues. Superoxide anions are implicated in a variety of diseases associated with pain and inflammation.

In addition, the Company's lead compound has the ability to substantially contribute to the pain relieving benefits associated with opioids. In a Phase II Clinical Trial, M40403 markedly improved the pain relief produced by opioids while making them more effective and more predictable. In independent tests by the National Institute on Drug Abuse, M40403 was found to have no addictive properties or abuse liability.

Metaphore has a global, multilayered intellectual property estate covering its broad class of compounds including composition of matter and use patents. This IP estate includes 70 issued and 63 pending worldwide patents.

Product candidates in U.S. clinical testing have broad therapeutic potential across a variety of diseases. Metaphore currently focuses its clinical development efforts in cancer and postoperative pain, rheumatoid arthritis and inflammatory disorders. These markets are significant in terms of scope and size. The company maintains offices in Fort Lee, New Jersey and St. Louis, Missouri. For more information on Metaphore, please visit the Web site at: http://www.metaphore.com/.

This press release contains forward-looking statements based on information available to Metaphore as of the date hereof. In some cases, you can identify these forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology. Metaphore's actual results could differ materially from the results stated or implied by such forward-looking statements due to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, general economic and business conditions, changes in governmental laws and regulations relating to the development and commercialization of pharmaceutical products, and competition in our industry. In addition, we are developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Metaphore disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Alan W. Dunton, MD http://www.profnet.com/ud_public.jsp?userid=347693

Metaphore Pharmaceuticals, Inc.

CONTACT: Alan W. Dunton, M.D., President and Chief Executive Officer,+1-201-582-5000, adunton@metaphore.com, or Sara E. K. Cooper, Director ofCorporate Communications, +1-201-582-5000, scooper@metaphore.com, both ofMetaphore Pharmaceuticals; or Scott M. Solomon, Vice President of SharonMerrill Associates, Inc., +1-617-542-5300, ssolomon@InvestorRelations.com; orMatt Dallas, Vice President of Financial Dynamics, +1-212-850-5627,mdallas@fd-us.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES